AC Immune (ACIU) Return on Capital Employed (2016 - 2026)
AC Immune (ACIU) posted quarterly Return on Capital Employed of 0.27% for Q1 2026, up 4176.0% year-over-year from 0.01% in Q1 2025, and up 282.13% quarter-over-quarter from 0.07% in Q4 2025.
AC Immune (ACIU) Return on Capital Employed (2016 - 2026) Analysis & Trends
AC Immune (ACIU) has reported Return on Capital Employed for 10 consecutive years, with 0.27% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 4176.0% year-over-year to 0.27%; the TTM figure through Mar 2026 stood at 0.27% (up 4176.0% YoY), while the FY2025 annual figure was 0.07%, up 5001.0% from the prior year.
- Return on Capital Employed improved to 0.27% in Q1 2026 per ACIU's latest filing, from 0.07% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 0.71% in Q2 2022 and bottomed at 87.05% in Q3 2025.
- Historically, Return on Capital Employed has averaged 34.88% across 5 years, with a median of 38.93% in 2022.
- Annual changes were most pronounced in 2022 — Return on Capital Employed plunged 8670 bps — and 2026, when it surged 4176 bps.
- AC Immune's Return on Capital Employed stood at 38.93% in 2022, then jumped by 101 bps to 0.39% in 2023, then tumbled by 9623 bps to 37.45% in 2024, then soared by 100 bps to 0.07% in 2025, then jumped by 282 bps to 0.27% in 2026.
- Business Quant data shows ACIU's Return on Capital Employed at 0.27% in Q1 2026, 0.07% in Q4 2025, and 87.05% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - | -0.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.06% |
| Mar 31, 2026 | 0.27% |
| Dec 31, 2025 | 0.07% |
| Sep 30, 2025 | -87.05% |
| Jun 30, 2025 | -51.30% |
| Mar 31, 2025 | -41.49% |
| Dec 31, 2024 | -37.45% |
| Sep 30, 2024 | -26.82% |
| Jun 30, 2024 | -58.34% |
| Mar 31, 2024 | -34.73% |
| Dec 31, 2023 | 0.39% |
| Sep 30, 2023 | -48.44% |
| Jun 30, 2023 | -42.98% |
| Mar 31, 2023 | -41.38% |
| Dec 31, 2022 | -38.93% |
| Sep 30, 2022 | -86.16% |
| Jun 30, 2022 | 0.71% |
| Mar 31, 2022 | 0.69% |
| Dec 31, 2021 | 0.40% |
| Sep 30, 2021 | 0.54% |